Sanofi to acquire diabetes treatment developer Provention Bio for $2.9B

Sanofi announced that it agreed to acquire Provention Bio, which develops therapeutics for immune-mediated diseases, for approximately $2.9 billion.

Paris, France-based Sanofi agreed to acquire Provention Bio for $25 per share in cash. If the companies complete the acquisition, Sanofi expects a wholly-owned subsidiary to merge with and into Provention Bio. It intends to fund the deal with available cash resources and expects it to close in the second quarter of 2023.

Provention Bio develops therapies focused on intercepting and preventing immune-mediated diseases, including type 1 diabetes. Sanofi said the acquisition adds Provention Bio’s fully owned, first-in-class type 1 diabetes therapy to its core asset portfolio in general medicines. It also drives Sanofi’s strategic shift toward products with a differentiated profile, according to a news release.

The FDA approved Tzield (teplizumab-mzwv) last year for delaying the onset of stage 3 type…

Read more
  • 0

Tzield drug that can delay onset of type 1 diabetes has a pricetag close to $200,000

The CD3 antigen inhibitor Tzield (teplizumab-mzwv) has won FDA approval to delay stage 3 type 1 diabetes in individuals at least 8 years old. 

A vial of Tzield will have a wholesale cost of $13,850, announced the drug’s developer Provention Bio (Nasdaq:PRVB). The drug is administered as an intravenous infusion once daily for 14 consecutive days, resulting in an overall cost of $193,900. 

Jason Hoitt

“How can one really value more time for a person — a child and their loved ones — without the psychological and physical impact that comes with stage 3 [type 1 diabetes] diagnosis?” asked Jason Hoitt, Provention Bio’s chief commercial officer, in a company presentation.

Hoitt said the FDA approval was “100 years in the making.” “The type 1 diabetes community has been waiting since the introduction of insulin for therapeutic advancement in the field.


Read more
  • 0